State Attorneys General Suing Compounders: The 2026 Enforcement Map

Federal regulators aren't the only ones with enforcement authority over compounded GLP-1s. State attorneys general have opened investigations, filed suits, and negotiated settlements with compounders and their telehealth partners. Here's the state-level pattern and what it means for patients.

The State AG Toolkit

State attorneys general have broad consumer protection authority. In the compounded GLP-1 context, that authority has been used to investigate: deceptive marketing practices (compounded product marketed as equivalent to brand); unlicensed telehealth prescribing across state lines; consumer refund and cancellation practices; and privacy/data handling by telehealth platforms holding sensitive health information.

The States Most Active in 2026

Enforcement activity has been most visible in states with large telehealth patient populations and active consumer protection divisions — California, New York, Texas, Florida, Massachusetts, and Washington, among others. Each state's actions typically focus on companies doing business in that state, so the enforcement map is uneven: a compounder or platform can be under scrutiny in one state and operating normally in another.

Pattern: Marketing Enforcement

Most state AG actions have focused on marketing rather than on the fact of compounding itself. Common enforcement theories include: implying FDA approval when compounded product doesn't have it; using brand names (Ozempic, Wegovy, Mounjaro, Zepbound) in ways that suggest equivalence; and quoting weight-loss statistics from brand-drug trials without proper attribution or context.

Platforms that have cleaned up marketing language — dropping brand-name references from ad copy and landing pages, adding clear "compounded, not FDA-approved" language, and citing generic clinical trial data properly — have generally been able to continue operations without disruption to patients.

Pattern: Consumer Protection

The other major enforcement pattern has been around consumer protection: platforms that charged for multi-month plans and didn't refund on cancellation, subscriptions that auto-renewed without clear disclosure, or care teams that pressured patients to escalate doses beyond what their intake supported. These are the actions that lead to consumer restitution — money back to patients — as part of settlements.

If you've experienced any of these patterns yourself, your state AG's consumer protection division accepts complaints, and complaints from patients are often what triggers investigation in the first place.

What Patients Can Check

Most state AG offices maintain public press-release pages announcing enforcement actions. Search your state AG's site for the platform or pharmacy name before enrolling. Existing action isn't automatically disqualifying — many enforcement settlements result in improved practices — but it's data worth having.

Where to Start